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Increases in Cerebral Atherosclerosis According to CHADS2
Scores in Patients With Stroke With Nonvalvular
Atrial Fibrillation
Young Dae Kim, MD; Myoung Jin Cha, MD; Jinkwon Kim, MD; Dong Hyun Lee, MD;
Hye Sun Lee, MS; Chung Mo Nam, PhD; Hyo Suk Nam, MD; Ji Hoe Heo, MD
Background and Purpose—The CHADS2 score is used for risk stratification of ischemic stroke in patients with
nonvalvular atrial fibrillation and high CHADS2 scores are associated with increased risk of stroke. Most components
of the CHADS2 score are also risk factors for atherosclerosis. Therefore, high CHADS2 scores can be associated with
concomitant cerebral atherosclerosis and subsequently atherothrombotic stroke. The aim of this study was to determine
whether there are differences in the presence and burden of concomitant cerebral atherosclerosis according to CHADS2
scores in patients with stroke with nonvalvular atrial fibrillation.
Methods—We included 780 consecutive patients with nonvalvular atrial fibrillation who had undergone angiographic
studies at index stroke between August 1994 and March 2010 in the present study. We investigated the relationships
between the CHADS2 score and the presence, severity, and pattern of cerebral atherosclerosis and stroke mechanism.
Results—Of the 780 patients, concomitant arterial stenosis (50%) was found in 231 patients (29.6%). The number of
arteries with atherosclerosis increased as the CHADS2 score increased (P0.001) as did the proportion of combined
extracranial and intracranial atherosclerosis (P0.001). Multivariate analyses showed that high risk based on the
CHADS2 score was an independent predictor of concomitant cerebral atherosclerosis (OR, 3.121; 95% CI, 1.770 to
5.504) and the presence of proximal stenosis at the symptomatic artery (OR, 3.043; 95% CI, 1.458 to 6.350).
Conclusions—The CHADS2 score can predict the presence of concomitant cerebral artery atherosclerosis. Increased risk
of stroke in patients with high CHADS2 scores may be partly explained by increased frequency and burden of cerebral
atherosclerosis. (Stroke. 2011;42:930-934.)
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Nonvalvular atrial fibrillation (NVAF) is a well-knownrisk factor of stroke, and maintaining an optimum intensity
of anticoagulation is highly effective for stroke prevention.1
However, serious bleeding complications, including intracere-
bral hemorrhage, are related to warfarin use,2,3 which limits its
routine use in patients with NVAF. Risk stratification schemes
have been developed to identify patients with high risks for
ischemic stroke or systemic embolic events and also to identify
patients eligible for anticoagulation.4,5
Currently, the CHADS2 index is widely used to stratify
patients with NVAF who are eligible for anticoagulation.
Increases in CHADS2 scores are associated with worsening
intracardiac thrombogenic conditions and increased risk of
embolic events.6,7 However, it is also possible that increased
risk of stroke with high CHADS2 scores is caused by
atherothrombotic mechanisms as well as cardioembolic
mechanisms, because most components of the CHADS2 score
are also risk factors for atherosclerosis. Although previous
studies indicated that approximately 20% to 50% of patients
with NVAF have severe stenotic lesions at the carotid
artery,8–10 few data are available regarding the relationship
between the presence of cerebral atherosclerosis in the entire
cerebral arterial beds and the CHADS2 score.
The aim of this study was to investigate whether there are
differences in atherosclerotic burden in cerebral arterial beds
according to risk levels based on CHADS2 scores and to assess




Between August 1994 and March 2010, a total of 6059 consecutive
patients with acute brain infarction or transient ischemic attack
within 7 days after symptom onset were admitted to our hospital and
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registered to the Yonsei Stroke Registry. During admission, all
patients were thoroughly investigated for demographic data, medical
history, vascular risk factors, and clinical manifestations.11 They all
underwent brain CT and/or MRI, 12-lead electrocardiography, and
standard blood tests. The presence of cerebral atherosclerosis was
investigated by digital subtraction angiography, MR angiography
(MRA), or CT angiography (CTA) during hospitalization. Stroke
subtypes and the presence of any abnormalities on angiographic
studies were determined prospectively at a weekly stroke conference
based on neuroradiologist reports and consensus of stroke specialists
and were entered into the stroke registry.11 This study was approved
by the Institutional Review Board of Severance Hospital, Yonsei
University Health System, and the requirement for informed consent
was waived.
Among 6059 patients, we excluded patients without atrial fibril-
lation (n4995) or those with atrial fibrillation and valvular heart
disease (n144). For analyses of concomitant cerebral atheroscle-
rosis, 140 patients who had not undergone angiographic studies were
further excluded. The final study sample consisted of a total of 780
patients with NVAF.
Clinical Variables
The CHADS2 score was calculated for each patient with 1 point
assigned to patients with a history of congestive heart failure,
hypertension, age 75 years, or diabetes mellitus and 2 points for a
history of stroke or transient ischemic attack. For this study, the
CHADS2 score was based on the previous diagnosis or clinical
history before the index stroke. The study sample was divided into 3
groups: low risk (CHADS2 score of 0), moderate risk (CHADS2
score of 1 or 2), and high risk (CHADS2 score of 3 to 6) based on
previous studies.4,5
The complete history of medication before admission was available
for 697 patients. Information regarding prior use of antithrombotics,
statins, and angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers was collected. Data for the international normalized
ratio at admission, smoking history, history of ischemic heart disease,
and hypercholesterolemia were also collected.
Concomitant Cerebral Atherosclerosis
The presence of steno-occlusive lesions of the cerebral artery was
investigated using the results of digital subtraction angiography in
265 (34.0%) patients, contrast-enhanced MRA in 386 (49.5%)
patients, and CTA in 129 (16.5%) patients among 780 patients
enrolled. Arterial stenosis was identified when the degree of stenosis
was 50% based on the North American Symptomatic Carotid
Endarterectomy Trial12 or Warfarin versus Aspirin for Symptomatic
Intracranial Disease method.13 The presence of arterial stenotic
lesions was determined for each arterial segment, including the
extracranial or intracranial internal carotid artery, the anterior cere-
bral artery, the middle cerebral artery, the extracranial or intracranial
vertebral artery, and the posterior cerebral artery on each side as well
as the basilar artery. When multiple stenotic lesions were observed in
1 arterial segment, data from the most severe stenotic lesion were
used. In patients with data for both digital subtraction angiography
and contrast-enhanced MRA or CTA, the results of digital subtrac-
tion angiography were used for analysis, and in patients with data for
both contrast-enhanced MRA and CTA, the results of CTA were
used for analysis.
For the analysis of concomitant cerebral atherosclerosis, we
included only steno-occlusive lesions after excluding symptomatic
arterial lesions to infracted areas. However, if a patient had a stenotic
lesion at the proximal carotid bulb or the orifice of the vertebral
artery, this lesion was considered the concomitant cerebral athero-
sclerotic lesion. Likewise, in cases with tandem stenotic lesions
(distal and proximal steno-occlusive lesions), we considered only the
proximal arterial lesion to be a concomitant cerebral atherosclerotic
lesion. After exclusion of the symptomatic arterial lesions, the
stenotic lesions were divided into isolated extracranial, isolated
intracranial, and combined extracranial and intracranial lesions. The
total number of stenotic arterial lesions was also calculated.
Statistical Analyses
Statistical analyses were performed using the Windows SPSS soft-
ware package (Version 18.0; Chicago, IL). Continuous variables
were compared with independent sample t tests, Mann-Whitney U
tests, Kruskal-Wallis tests, or analysis of variance, and categorical
variables with 2 tests, as appropriate. Post hoc analyses were
conducted with the Scheffe test. The increasing proportions of
clinical variables according to the CHADS2 score were compared
using the Mantel-Haenszel test. The relationship between numbers of
lesions and CHADS2 scores was determined by Spearman rank test.
Multivariate logistic analysis was used to compute the ORs of
covariates, including the CHADS2 score, when determining inde-
pendent factors predicting concomitant cerebral atherosclerosis or
the presence of proximal arterial stenosis.
Results
The baseline characteristics of the 780 patients enrolled in
this study are provided in Table 1. Among 697 patients for
whom a complete medication history was obtainable, warfa-
rin use with optimum intensity (international normalized
ratio, 2 to 3) was observed in only 32 patients (4.6%).
According to CHADS2 scores, there was an increasing trend
of having the components of the CHADS2 index (P0.001)
and receiving prior cardiovascular medications, except for
anticoagulants.
Table 1. Baseline Characteristics of the Study Sample
Characteristics Numbers or Means
Age, years 69.510.5
Sex, male 446 (57.2)
Paroxysmal atrial fibrillation 101 (12.9)
Congestive heart failure 137 (17.6)
Hypertension 569 (72.9)
Age 75 years 252 (32.3)
Diabetes mellitus 186 (23.8)
Hypercholesterolemia 73 (9.4)
Previous ischemic stroke or transient ischemic attack 128 (16.4)
Smoking
Current smoker 102 (13.1)
Exsmoker 136 (17.4)













Angiotensin-converting enzyme inhibitor 91 (13.1)
Angiotensin receptor blocker 151 (21.7)
Data are given as the no. (percentage) or meanSD.
*Data were analyzed for 697 patients whose complete medication history
was obtainable.
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Concomitant Cerebral Atherosclerosis According
to the CHADS2 Score
In total, 231 patients (29.6%) were found to have atherosclerosis
(50%) in1 arteries at any cerebral arterial bed. Among these,
isolated intracranial stenosis (47.6% [110 of 231]) was the most
commonly involved location followed by isolated extracranial
stenosis (33.8% [78 of 231]) and combined extracranial and
intracranial stenosis (18.6% [43 of 232]). If we included all
steno-occlusive lesions with the baseline angiographic studies,
involvement of the middle cerebral artery was most common.
However, after exclusion of the symptomatic arterial lesion, the
extracranial vertebral artery was the most common artery in-
volved followed by the middle cerebral artery and the extracra-
nial internal carotid artery (Table 2).
There was a positive correlation between the CHADS2
score and the number of arteries affected by concomitant
cerebral atherosclerosis (r0.187, P0.001). The burden of
the concomitant cerebral atherosclerosis increased in an
incremental fashion according to the CHADS2 score when the
number of stenotic arteries was divided into 4 groups such as
0, 1, 2, 3, or4 (P0.001; Figure A). An increasing tendency
for concomitant cerebral atherosclerosis was observed in all
cerebral arterial beds as the CHADS2 score increased (Figure B).
Concomitant cerebral atherosclerosis was observed in 20 pa-
tients (19.2%) in the low-risk group, 128 (27.0%) in the
moderate-risk group, and 83 (41.1%) in the high-risk group. In
particular, the proportion of combined extracranial and intracra-
nial stenoses was relatively larger in the high-risk group than in
the low- or moderate-risk group (Figure B).
The factors related to concomitant cerebral atherosclerosis
were determined. Univariate analysis identified age
(71.710.4 years with atherosclerosis versus 68.610.5
years without, P0.001), hypertension (P0.001), diabetes
mellitus (P0.017), and previous stroke or transient ischemic
attack (P0.019) along with belonging to the high-risk group
(P0.001) were associated with the presence of concomitant
cerebral atherosclerosis. Multivariate logistic regression anal-
ysis revealed that belonging to the high-risk group with
CHADS2 scores of 3 to 6 was a significant and independent
predictor for concomitant cerebral atherosclerosis (Table 3).
Among components of the CHADS2 score, hypertension, age
75 years, and previous ischemic stroke were determinants
of cerebral atherosclerosis in patients with NVAF. When we
further analyzed the data of digital subtraction angiography
only, the high-risk group was also an independent and
significant predictor for concomitant cerebral atherosclerosis
(Supplemental Table I, http://stroke.ahajournals.org).
Stroke Mechanism According to the
CHADS2 Score
Of 780 patients, 21 patients had transient ischemic attack
without a relevant acute ischemic lesion on brain imaging
studies. The stroke mechanism was investigated in 759
patients who had neurological symptoms and clinically rele-
vant ischemic lesions on brain imaging.
In this sample, 128 patients (16.9%) had a proximal
stenotic lesion at the symptomatic artery, which suggests that
the atherothrombotic mechanism could be a possible cause of
ischemic stroke. Proximal atherosclerotic lesions were most
frequently found in the high-risk group (24.0% [46 of 192])
followed by the moderate-risk (15.5% [72 of 465]) and
low-risk groups (9.8% [10 of 102]), and these differences
were significant (P0.001). Among components of the
CHADS2 score, hypertension (P0.001) and previous ische-
mic stroke (P0.001) were associated with the presence of
proximal atherosclerotic lesions. Other variables including
age 75 years, diabetes mellitus, smoking, hyperlipidemia,
previous ischemic heart disease, and prior medication before
Figure. The increasing trend of cerebral athero-
sclerosis according to the risk level based on the
CHADS2 score. A, Total number of the atheroscle-
rotic lesions; (B) distribution of cerebral
atherosclerosis.







Extracranial internal carotid artery 56 (7.2) 95 (12.2)
Intracranial internal carotid artery 21 (2.7) 45 (5.8)
Anterior cerebral artery 35 (4.5) 47 (6.0)
Middle cerebral artery 57 (7.3) 237 (30.4)
Extracranial vertebral artery 76 (9.7) 86 (11.0)
Intracranial vertebral artery 34 (4.4) 47 (6.0)
Basilar artery 13 (1.7) 38 (4.9)
Posterior cerebral artery 50 (6.4) 76 (9.7)
Data are given as the no. (percentage).
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the stroke were not significant determinants in univariate
analysis. Multivariate analysis revealed that high risk based
on the CHADS2 score was associated with the presence of
proximal arterial stenosis compared with the low-risk group.
Among components of the CHADS2 score, hypertension and
previous ischemic stroke were significant predictors of prox-
imal atherosclerotic lesions (Table 4).
Discussion
We have demonstrated that cerebral atherosclerosis is more
common in patients with higher CHADS2 scores and that
these patients also have higher risks of atherothrombotic
stroke as well as cardioembolic stroke.
In our study sample, approximately one third of the
patients demonstrated significant atherosclerotic lesions in
the cerebral artery other than the steno-occlusive lesion in the
symptomatic arteries. The frequency and burden of cerebral
atherosclerosis increased with increases in the CHADS2 score.
Among components of the CHADS2 score, older age, hyperten-
sion, diabetes, and previous ischemic stroke are well-known
vascular risk factors for atherosclerosis and first-ever or recur-
rent ischemic stroke. The frequency or burden of cerebral
atherosclerosis escalates with increasing numbers of vascular
risk factors,14 and such increases may also occur in patients with
NVAF. Along with the known contributory roles of the compo-
nents of the CHADS2 score on atherosclerosis, our findings
indicate that the risk of cerebral atherosclerosis increases as the
CHADS2 score increases.
A previous study showed that the frequency of the left
atrial or left atrial appendage thrombus increased with the
ascending CHADS2 score, which suggests that the compo-
nents of the CHADS2 score may enhance the thrombogenic
milieu in the intracardiac chamber.6,7 Such changes in the
intracardiac chamber may increase the risk of cardioembo-
lism. However, the risk of atherothrombotic stroke in patients
with NVAF may also increase in patients with higher
CHADS2 scores. In patients with NVAF, not only cardioem-
bolic, but also noncardioembolic ischemic stroke can oc-
cur.9,15 In our study, patients included in the high-risk group
more frequently had combined extracranial and intracranial
stenosis and proximal stenotic lesions of the symptomatic
artery. The incidence of ischemic and total cerebrovascular
events was greater in patients with combined extracranial and
intracranial stenosis than in patients with only isolated ex-
tracranial or intracranial stenosis.14 Given that artery-to-artery
embolism from the proximal atherosclerotic plaques is the main
stroke mechanism in atherothrombotic stroke,9 the proximal
arterial lesions may actually cause stroke in some patients with
NVAF. In this regard, increased risk of stroke in patients with
higher CHADS2 scores may be associated with increased risk of
atherothrombotic stroke in addition to preexisting atrial
fibrillation-related risk of cardioembolic stroke.
Patients with higher CHADS2 score may require additional
measures for prevention of ischemic stroke because concom-
itant cerebral atherosclerosis was frequent in those groups.
The measures may include combined use of an antiplatelet
Table 3. Multivariate Analysis Regarding Concomitant Cerebral Atherosclerosis
OR (95% CI) P OR (95% CI) P
Male sex 1.416 (1.027–1.951) 0.034 1.558 (1.117–2.173) 0.009
CHADS2 score
Low risk, 0 Reference . . . . . .
Moderate risk, 1–2 1.625 (0.956–2.764) 0.073 . . . . . .
High risk, 3–6 3.121 (1.770–5.504) 0.001 . . . . . .
CHADS2 score component
Hypertension . . . . . . 1.859 (1.254–2.755) 0.002
Age 75 years . . . . . . 1.990 (1.419–2.791) 0.001
Diabetes mellitus . . . . . . 1.423 (0.994–2.036) 0.054
Previous ischemic stroke
before index stroke
. . . . . . 1.527 (1.017–2.294) 0.041
Table 4. Multivariate Analysis Regarding the Presence of Proximal Arterial Stenosis
OR (95% CI) P OR (95% CI) P
Male sex 1.339 (0.903–1.987) 0.146 1.390 (0.926–2.085) 0.112
CHADS2 score
Low risk, 0 Reference . . . . . .
Moderate risk, 1–2 1.747 (0.866–3.524) 0.119 . . . . . .
High risk, 3–6 3.043 (1.458–6.350) 0.003 . . . . . .
CHADS2 score component
Hypertension . . . . . . 3.043 (1.720–5.382) 0.001
Age 75 years . . . . . . 1.392 (0.922–2.102) 0.115
Previous ischemic stroke
before index stroke
. . . . . . 1.930 (1.213–3.070) 0.005
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drug and warfarin as well as strict risk factor controls.
However, in case of combined use of an anticoagulant and
antiplatelet drugs, increased risks of hemorrhagic complica-
tions also should be considered, in particular in Asian patients
who are vulnerable to intracranial hemorrhage. Alternatively,
combined use of antiplatelet agents and a direct thrombin
inhibitor, 110 mg Dabigatran, which had less hemorrhagic
complications than warfarin,16 or closure of the left atrial
appendage may be considered.
There are some limitations in this study. First, this is a
retrospective study and angiographic results with various
modalities were used for the investigation of cerebral arterial
stenosis. Although contrast-enhanced MRA had higher sen-
sitivity than other imaging modalities such as CTA or
MRA,17,18 Contrast-enhanced MRA also might produce an
artifactual overestimation of arterial stenosis in some pa-
tients.19 Second, in our study, stenotic lesions were more
common in the intracranial artery than in the extracranial
artery, possibly due to ethnic characteristics. Intracranial
atherosclerosis, especially isolated intracranial artery steno-
sis, is more common in East Asians than in Westerners.20–23
Stenosis or occlusion of the symptomatic intracranial artery
can be either due to embolism from the heart or in situ
thrombosis/arterial embolism from the atherosclerotic lesion.
These lesions often cannot be differentiated on angiographic
studies. Therefore, steno-occlusion of the symptomatic intra-
cranial artery was not considered as an atherosclerotic lesion
in our analysis. This definition in our study might lead to an
underestimation of the frequency of intracranial artery ath-
erosclerosis and the atherothrombotic mechanism attributed
to intracranial artery atherosclerosis.
Conclusions
The results of our study suggest that the presence and burden of
cerebral atherosclerosis can be predicted by CHADS2 scores.
Our findings also suggest that atherothrombosis should be
considered to be a potential stroke mechanism in patients with
high CHADS2 scores. Approximately 40% of high-risk patients
(CHADS2 score3) have significant stenosis of the large artery
that may necessitate interventional treatment in some patients for
improved stroke prevention. These patients may also require
additional antithrombotic treatment. In this regard, strict evalu-
ation of cerebral atherosclerosis should be considered in patients
with higher CHADS2 scores.
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Supplemental table. Multivariate analysis regarding concomitant cerebral atherosclerosis with the data of DSA 
 
 








Male sex 1.268 (0.716 - 2.245) 0.416 1.292 (0.730 -2.286) 0.380 
CHADS2 score         
 Low risk (0) reference    -  - 
 Moderate risk (1-2) 0.805 (0.368 - 1.762) 0.588  -  - 
 High risk (3-6) 2.703 (1.140 - 6.410) 0.024  -  - 
CHADS2 score component         
 Age ≥75  -  - 1.311 (0.696 - 2.472) 0.402 
 Diabetes  -  - 1.869 (1.002 - 3.486) 0.049 
 Previous ischemic stroke before index stroke  -  - 2.231 (1.111 - 4.481) 0.024 
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Increases in Cerebral Atherosclerosis According to CHADS2 Scores in Patients 
With Stroke With Nonvalvular Atrial Fibrillation
Young Dae Kim, MD; Myoung Jin Cha, MD; Jinkwon Kim, MD; Dong Hyun Lee, MD;Hye Sun Lee, MS; 
Chung Mo Nam, PhD; Hyo Suk Nam, MD; Ji Hoe Heo, MD
背景及目的：CHADS2 评分用于非瓣膜性心房颤动患者的缺血性卒中危险分层，较高的 CHADS2 分数与卒中
风险增加相关。CHADS2 评分的大部分组成部分也是动脉粥样硬化的危险因素。因此，较高的 CHADS2 分数
与脑动脉粥样硬化及相应的动脉粥样硬化血栓形成性卒中有关。本研究目的是了解不同 CHADS2 评分的非瓣
膜性心房颤动卒中患者的脑动脉粥样硬化患病及严重程度是否有所不同。
方法：本研究包括 1994年 8月至 2010年 3月的 780例连续的、接受血管造影检查的非瓣膜性心房颤动卒中患者。
分析 CHADS2 评分与脑动脉粥样硬化的患病、严重程度、类型以及卒中发生机制的关系。
结果：780 例患者中，发现 231 例 (29.6%) 合并动脉狭窄 ( ≥ 50%)。动脉粥样硬化的动脉数量随 CHADS2 分数
增加而增加 (P<0.001)，颅内和颅外动脉粥样硬化的比例亦随评分增加而增加 (P<0.001)。多变量分析表明，基
于 CHADS2 评分的高风险也是脑动脉粥样硬化 (OR，3.121；95% CI，1.770-5.504) 及症状相关动脉近端狭窄 (OR，
3.043 ；95% CI，1.458-6.350) 的独立预测因素。
结论：CHADS2 评分可以预测脑动脉粥样硬化的存在。高 CHADS2 评分患者的高卒中风险可能部分原因是脑
动脉粥样硬化的发生和严重程度增加。
关键词：动脉粥样硬化，房颤，CHADS2 评分，卒中
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血栓形成机制相关。尽管早先已有很多研究表明大








收集 1994年 8月至 2010年 3月在我院住院治
疗同时在 Yonsei卒中登记中心 (Yonsei Stroke Regis-
try)登记的发病 7天内的急性脑梗死或短暂性脑缺血
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发作 (TIA)病例，共 6059例。在住院期间，所有患
者均彻底调查了人口学数据、病史记录、血管危险

















记 1分，既往卒中或 TIA史记 2分。在本研究中，
CHADS2评分是基于卒中发病前的诊断和临床病史。
根据先前的研究方法，分研究样本为低危组 (CHADS2








在纳入的 780例患者中，有 265例患者 (34.0%)
的大脑动脉狭窄或闭塞是通过 DSA来检查，386例























的 t检验、Mann-Whitney U检验、Kruskal-Wallis 检
验或方差分析。分类变量采用卡方检验。用 Scheffe






























　ACEI  91 (13.1)
　ARB 151 (21.7)
通过数目 ( 百分比 ) 或均数±标准差给出数据。
* 对 697 例有完整的住院前药物治疗病史的患者进行的数据分析。
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 OR(95% CI) P OR(95% CI) P
男性 1.416(1.027-1.951) 0.034 1.558(1.117-2.173) 0.009
CHADS2 评分    
　低危，0 参考  … …
　中危，1-2 1.625(0.956-2.764) 0.073 … …
　高危，3-6 3.121(1.770-5.504) <0.001 … …
CHADS2 评分成分    
　高血压 … … 1.859(1.254-2.755) 0.002
　年龄 ≥75 岁 … … 1.990(1.419-2.791) <0.001
　糖尿病 … … 1.423(0.994-2.036) 0.054
　既往缺血性卒中 … … 1.527(1.017-2.294) 0.041
表 4　关于近端动脉狭窄的多变量分析
　	 OR(95% CI) P OR(95% CI) P
男性	 1.339(0.903-1.987) 0.146 1.390(0.926-2.085) 0.112
CHADS2 评分	    
　低危，0 参考	  … …
　中危，1-2 1.747(0.866-3.524) 0.119 … …
　高危，3-6 3.043(1.458-6.350) 0.003 … …
CHADS2 评分成分	    
　高血压	 … … 3.043(1.720-5.382) <0.001
　年龄 ≥75 岁	 … … 1.392(0.922-2.102) 0.115
　既往缺血性卒中	 … … 1.930(1.213-3.070) 0.005
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